Impact of Prior Antiplatelet Therapy on Risk of Embolism in Infective Endocarditis
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Embolism is a dreaded complication of infective endocarditis (IE). Currently, antimicrobial therapy is the only medical intervention proven to decrease the risk of embolism associated with IE. We hypothesized that, because platelet aggregation is operative in the pathogenesis of vegetation formation, embolism associated with IE should occur less frequently among patients who have received prior, continuous daily antiplatelet therapy for noninfectious reasons. METHODS: We studied a retrospective cohort of adult patients with a diagnosis of IE who presented to the Mayo Clinic (Rochester, MN) during 1980-1998. The cohort was divided into 2 groups on the basis of whether they had received continuous daily antiplatelet therapy for at least 6 months prior to the time of hospitalization for IE. Antiplatelet therapy included aspirin, dipyridamole, clopidogrel, ticlopidine, or any of combination of these agents. The primary end point was a symptomatic embolic event that occurred prior to or during hospitalization. Multivariable logistic regression was used to assess the impact of continuous daily antiplatelet therapy on risk of symptomatic emboli associated with IE. RESULTS: One hundred forty-seven (24.5%) of 600 patients experienced a symptomatic embolic event; the most common embolic manifestation was stroke (in 48.2% of patients). Embolic events occurred significantly less often among those who had received prior, continuous daily antiplatelet therapy (12.0% of patients who had received therapy vs. 27.8% patients who had not receive therapy; P<.001). After adjustment for several covariates known to influence both risk of embolism and propensity for antiplatelet use, the adjusted odds ratio for a symptomatic embolic event was 0.36 (95% confidence interval, 0.19-0.68; P=.002) for patients receiving continuous daily antiplatelet therapy. CONCLUSIONS: The risk of symptomatic emboli associated with IE was reduced in patients who received continuous daily antiplatelet therapy before onset of IE.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Retrospective, observational studies 290-296 have examined the impact, if any, of long-term antiplatelet therapy before the onset of IE on infection-related outcomes.Findings from these investigations have been mixed in terms of IE-related outcomes.”
Citations
Cites
The environment and disease: association or causation?
Hill, A. B. (2015) · Journal of the Royal Society of Medicine · doi:10.1177/0141076814562718 · Cited by 7,285
The Environment and Disease: Association or Causation?
Hill, A. B. (1965) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591576505800503 · Cited by 6,974
Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
Li, J. S., Sexton, D. J., Mick, N., Nettles, R., Fowler, V. G., Ryan, T., Bashore, T., & Corey, G. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313753 · Cited by 4,027
Bulletin of the World Health Organization
C., N. H. (1955) · The British Journal of Sociology · doi:10.2307/587237 · Cited by 3,601
Estimating Causal Effects from Large Data Sets Using Propensity Scores
Rubin, D. B. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-8_part_2-199710151-00064 · Cited by 2,877
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Self-citationExperience from a multicentre stroke register: a preliminary report.
Hatano, S. (1976) · Europe PMC (PubMed Central) · Cited by 1,526
Patrono, C., Coller, B., Dalen, J. E., Fitz Gerald, G. A., Fuster, V., Gent, M., Hirsh, J., & Roth, G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.39s · Cited by 963
(1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251801 · Cited by 759
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects
Patrono, C., Coller, B., FitzGerald, G. A., Hirsh, J., & Roth, G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.234s · Cited by 671
Cited by
Items 101–142 of 142
Impact of Antiplatelet Therapy on Clinical Manifestations and Outcomes of Cardiovascular Infections
Habib, A., Baddour, L. M., & Sohail, M. R. (2013) · Current Infectious Disease Reports · doi:10.1007/s11908-013-0347-z · Cited by 4
Self-citationNeurologic Manifestations of Infective Endocarditis
Williams, L. S., & Brosch, J. R. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407710-2.00006-0 · Cited by 4
Palraj, R., Knoll, B. M., Baddour, L. M., & Wilson, W. R. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00083-7 · Cited by 4
Self-citationGarrigos, Z. E., & Sohail, M. R. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz353 · Cited by 4
Can patients with infectious endocarditis be safely anticoagulated?
Randhawa, M. S., Pile, J. C., & Gomes, M. P. V.-F. (2016) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.83a.15027 · Cited by 3
Salehian, O., & Chan, K. (2016) · Springer eBooks · doi:10.1007/978-3-319-27784-4_13 · Cited by 3
Wang, J., Hou, J., Feng, K., Wu, H., Liu, Q., Zhou, Z., Li, H., Luo, L., Fu, G., Shang, L., et al. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.131432 · Cited by 3
Pisaryuk, A. S., Zamarashkina, V. A., Safarova, N. B., Povalyaev, N. M., Олеговна, К. Е., Babukhina, J. I., Михайловна, К. Е., & Kobalava, Z. D. (2022) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2022-06-14 · Cited by 3
Hoen, B., Tornos, P., Antunes, M. J., Lekakis, J. P., Lengyel, M., Naber, C. K., & Zamorano, J. L. (2009) · Cited by 3
Haemophilus parainfluenzaeprosthetic valve endocarditis complicated by septic emboli to brain
Liang, J. J., Swiecicki, P. L., Killu, A. M., & Sohail, M. R. (2013) · BMJ Case Reports · doi:10.1136/bcr-2013-009744 · Cited by 3
Habib, G., Hoen, B., Tornos, P., Thuny, F., Prendergast, B., Vilacosta, I., Moreillon, P., Antunes, M. J., Thilén, U. J., Lekakis, J. P., et al. (2009) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(09)73540-6 · Cited by 3
Which therapy for which condition?
Gersh, B. J., & Opie, L. H. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-3322-4.00021-1 · Cited by 3
Samad, Z. Z., & Wang, A. (2009) · Wiley eBooks · doi:10.1002/9781444309768.ch59 · Cited by 2
Role of Neuro-Interventions and Surgery for Infectious Brain Complications
Obiri‐Yeboah, D., Wottrich, S., Achey, R., & Bain, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-65839-6_13 · Cited by 2
Roosens, B., Brewée, S., SUTTER, J. D., Motoc, A. I., Willems, A., Vervloet, D., Galloo, X., Unger, P., Prihadi, E. A., Droogmans, S., et al. (2025) · Journal of the Heart Valve Society · doi:10.1177/30494826251336319 · Cited by 2
One-and-a-half syndrome: a less appreciated emergency in native valve infective endocarditis
Tsai, W., Chen, W.-L., & Tsao, Y. (2012) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2012.08.005 · Cited by 2
Prevention and Treatment of Infective Endocarditis
Stancoven, A., & Peterson, G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00043-6 · Cited by 2
Levine, D. P. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0109-0 · Cited by 2
Anavekar, N. S., & Murphy, J. G. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0115-2 · Cited by 2
Self-citationVeloso, T. R., Que, Y., Moreillon, P., & Entenza, J. M. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv133 · Cited by 2
Infective Endocarditis Revealed by Ischemic Stroke in a Young Patient
Bouzekraoui, I., Lahraoui, M., Benhlima, A., Doumiri, M., & Amor, M. (2025) · Cureus · doi:10.7759/cureus.96935 · Cited by 1
2025 Clinical practice guidelines for Infectious endocarditis and infection of intracardiac devices
Кобалава, Ж. Д., Демин, А. А., Titov, D. A., Kozlov, R. S., Artyukhina, Е. А., Boytsov, S. A., Golukhova, E. Z., Гордеев, М. Л., Gudymovich, V. D., А., Д. Е., et al. (2026) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2026-6853 · Cited by 1
Paz, J. (2013) · Saúde & tecnologia/Saúde & tecnologia · doi:10.25758/set.654 · Cited by 1
Which Therapy for Which Condition?
Gersh, B. J., & Opie, L. H. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-6158-8.50017-4 · Cited by 1
Guidelines for When to Operate in Infective Endocarditis
Habib, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-32432-6_22 · Cited by 1
Antithrombotic Therapy in Valvular Heart Disease
Droogmans, S., Vanhentenrijk, S., & Cosyns, B. (2019) · Springer eBooks · doi:10.1007/978-3-030-23104-0_16 · Cited by 1
Tvivo, A., Rokach, A., Ben-David, E., Simons, M., & Heyman, S. N. (2023) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2023_004044 · Cited by 1
Neurological Complications in Infective Endocarditis
Snygg‐Martin, U. (2016) · Springer eBooks · doi:10.1007/978-3-319-32432-6_12 · Cited by 1
Antiplatelet Therapy in Staphylococcus aureus Bacteremia: No Time Like the Past?
Mourad, A., Holland, T. L., & Turner, N. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00365-22 · Cited by 1
Riconoscimento ecocardiografico di endocardite infettiva a elevato rischio embolico
Parato, V. M., & Piceno, A. (2007)
Luaces, M. (2009) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Nontraditional Anti - Infectious Agents in Hemodialysis
Sedlacek, M. (2011) · InTech eBooks · doi:10.5772/22853
Cerebral complications in infective endocarditis
Snygg‐Martin, U. (2009) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Infective Endocarditis in the Older Adult: An Emerging Entity in Need of a Specific Approach
Hermans, H., Herijgers, P., Claus, P., Peetermans, W. E., & Herregods, M. (2009) · Aging Health · doi:10.2217/ahe.09.13
Plata, A. (2016) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Wang, Y.-C., Chiang, T.-T., Chen, J.-H., Sun, J., Yin, T., Yang, Y., Lin, T., Chiu, S.-K., Yeh, K., Wang, N., et al. (2018) · Journal of Medical Sciences · doi:10.4103/jmedsci.jmedsci_67_18
Task Force Esc (2010) · Giornale italiano di cardiologia · doi:10.1714/663.7719
Aslanidi, I. P., Пурсанова, Д. М., Мухортова, О. В., Владимировна, Ш. И., Екаева, И. В., Serguladze, S. Y., Муратович, М. Р., Мироненко, В. А., & Александрова, С. А. (2019) · The Bulletin of Bakoulev Center Cardiovascular Diseases · doi:10.24022/1810-0694-2019-20-11-12-1070-1077
Roach, E. S., Bettermann, K., & Biller, J. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9781139644235.011
Effect of antiplatelet drugs on platelet-bacteria interactions
Hannachi, N. (2020) · theses.fr (ABES) · doi:10.70675/1a21a955z026cz4417z8e21z7c2334f75c79
Prognostic impact of previous and new myocardial infarction in patients with infective endocarditis
Lara-Gonzalez, M., Muñóz, P., Pedraz, Á., Delgado‐Montero, A., Cobo-Belaustegui, M., Fariñas, M. C., de Alarcón, A., Esteban, Á. R., Goenaga-Sánchez, M. Á., Lopez-Azor, J. C., et al. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2026.134508
Altıner, S., & Tanrıöver, M. D. (2026) · International Journal of Current Medical and Biological Sciences
Metadata
- Authors
- Anavekar, N. S., Tleyjeh, I. M., Anavekar, N. S., Mirzoyev, Z., Steckelberg, J. M., Haddad, C., Khandaker, M. H., Wilson, W. R., Chandrasekaran, K., & Baddour, L. M.
- Affiliations
- King Fahd Medical City (SA)
- Mayo Clinic (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-05-01
- Volume
- 44
- Issue
- 9
- Pages
- 1180-1186
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2149023309
- Semantic Scholar
- eda90418fcdc68283dde09b5ba5c8a029226bcb1
- Cited by
- 138
- References
- 44
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 4 · 2023: 8 · 2022: 8 · 2021: 7 · 2020: 12 · 2019: 5 · 2018: 3 · 2017: 1 · 2016: 7 · 2015: 9 · 2014: 10 · 2013: 11 · 2012: 8
- FWCI
- 6.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mayo Clinic
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cardiovascular and Diving-Related Complications
- Keywords
- infective endocarditis, embolism, antiplatelet therapy, aspirin, clopidogrel, ticlopidine, dipyridamole, stroke, platelet aggregation, embolic complications
- MeSH terms
- Clopidogrel, Aged, Aspirin, Dipyridamole, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Embolism, Endocarditis, Bacterial, Female, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Retrospective Studies, Ticlopidine, Incidence, Prevalence, Risk Assessment, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.